Discontinued — last reported Q4 '19
JPMorgan Chase Loans collectively evaluated for impairment increased by 4.1% to $1.42T in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.5%, from $1.29T to $1.42T.
other_financing_receivable_collectively_evaluated_for_im_e5b141| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $944.29B | $956.38B | $1.00T | $1.04T | $1.05T | $1.08T | $1.25T | $1.26T | $1.26T | $1.27T | $1.28T | $1.29T | $1.34T | $1.36T | $1.42T |
| QoQ Change | — | +1.3% | +4.7% | +3.5% | +1.6% | +2.5% | +15.8% | +0.8% | -0.2% | +0.7% | +1.0% | +1.2% | +3.4% | +1.8% | +4.1% |
| YoY Change | — | — | — | +9.8% | +10.1% | +7.7% | +20.6% | +19.7% | +16.6% | +1.4% | +1.5% | +2.9% | +5.6% | +6.4% | +9.5% |